Clinical trials: Steatosis
Non-Alcoholic Steatohepatitis (NASH), Type2 Diabetes Mellitus
A Pilot Study to Assess the Safety of Oral Insulin in Patients With Nonalcolholic Steatohepatitis (NASH)
This is an open, pilot study using the oral ORMD-0801 insulin formulation in patients with NASH and confirmed type 2 DM or pre-diabetes.
- Trial name
- NCT02653300
- Testing
- Oral Insulin
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Oramed, Ltd.
Diabetes Mellitus, Type 2, Metabolic Associated Fatty Liver Disease
Correlation Between Serum Nociceptin and Sympathetic Nerve Activity in Diabetic Patients With MAFLD
This observational study aims to investigate the relationship between serum nociceptin levels and sympathetic nervous system activity in patients with both type 2 diabetes mellitus (T2DM) and metabolic associated fatty liver…
- Trial name
- NCT07663682
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Second Hospital of Shanxi Medical University
Non-alcoholic Steatohepatitis
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)
Semaglutide is a medicine studied in patients with NASH. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabetes in many countries.
- Trial name
- ESSENCE (NCT04822181)
- Testing
- Semaglutide
- Where
- 558 sites in United States, Argentina and 37 more
- Volunteers
- 1,205 people
- Sponsor
- Novo Nordisk A/S
Steatohepatitis, Nonalcoholic, Steatosis
Nutritional Intervention IN Nash NON-ALCOHOLIC (NAFLD).
The goal of this randomized clinical trial with adults is to discuss the effectiveness of the nutritionist's educational interventions in users diagnosed with NAFLD, compared to the usual medical follow-up of users treated at the…
- Conditions
- Steatohepatitis, Nonalcoholic, Steatosis, Liver Diseases, Steatohepatitis
- Trial name
- NUTRINAFLD (NCT05946330)
- Testing
- NUTRITIONAL EDUCATIONAL INTERVENTION IN FATTY LIVER DISEASE NON-ALCOHOLIC (NAFLD).
- Where
- Brazil
- Volunteers
- 10 people
- Sponsor
- Universidade Federal do Paraná
Liver Steatoses
Observational and Prospective Study of Hepatic Steatosis and Related Risk Factors Using Ultrasound and Artificial Intelligence
Fatty liver is the most frequent chronic liver disease worldwide and ultrasonography is widely employed for diagnosis. The accuracy of this technique, however, is strongly operator-dependent.
- Trial name
- ST-AI (NCT06103175)
- Where
- Italy
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University of Bari
Steatosis
Clinical Validation of a Raman Spectroscope to Determine Hepatic Fat Content
Fatty liver disease including liver steatosis (fat deposition) is a major health problem worldwide. It is considered pathological when fat accumulation exceeds 5% of the liver weight.
- Trial name
- NCT02621853
- Testing
- Raman spectroscopy of the liver
- Volunteers
- 3 people
- Sponsor
- Nova Scotia Health Authority
Insulin Resistance, Type2 Diabetes Mellitus
High-fat Overfeeding, Hepatokines and Appetite Regulation
The present study will investigate the effect of high-fat overfeeding on a group of liver-secreted proteins linked to worsened blood sugar control, as well as proteins involved in appetite control.
- Conditions
- Insulin Resistance, Type2 Diabetes Mellitus, Non-Alcoholic Fatty Liver Disease, Obesity
- Trial name
- OVEREAT (NCT03369145)
- Testing
- High-fat diet
- Where
- 2 sites in United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Loughborough University
Non-Alcoholic Fatty Liver Disease, Fatty Liver
Effect of Probiotic and Smectite Gel on NAFLD
Smectite is a natural silicate clay belonging to the dioctahedral smectite class and has the ability directly to absorb bacterial toxins, bacteria, viruses and bile salts.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Fatty Liver, Liver Diseases, Digestive System Diseases
- Trial name
- NCT03614039
- Testing
- "Symbiter Forte"
- Volunteers
- 50 people
- Sponsor
- Nazarii Kobyliak
Non Alcoholic Steatohepatitis
The Effects of Flaxseed Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
To study the effects of Flaxseed supplement on lipid profile, liver enzymes, inflammatory factors and hepatic fibrosis in patients with Nonalcoholic Steatohepatitis (NASH), 50 patients who referred to Gastrointestinal (GI) clinic…
- Trial name
- NCT02395900
- Testing
- Flaxseed, control
- Volunteers
- 50 people
- Sponsor
- National Nutrition and Food Technology Institute
Non-Alcoholic Steatohepatitis
Safety and Tolerability Study of SHP626 in Overweight and Obese Adults
This study will investigate the safety and tolerability of daily dosing regimens of SHP626 in overweight and obese adults.
- Trial name
- NCT02287779
- Testing
- SHP626
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Mirum Pharmaceuticals, Inc.
Hepatic Steatosis
Hepatic Steatosis After Cholecystectomy
The investigators are very pleased to register the study entitled "A prospective study for the effect of cholecystectomy to the liver in consideration of hepatic steatosis 3months after cholecystectomy with Ultrasound".
- Trial name
- HSAC (NCT02493153)
- Testing
- Laparoscopic Cholecystectomy
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Sangchul Yun
Compensated Liver Cirrhosis, Metabolic Dysfunction Associated Steatohepatitis (MASH)
A Study to Test How Well BI 770371 is Tolerated by People With Cirrhosis Caused by a Liver Disease Called MASH
This study is open to people with cirrhosis caused by a liver disease called MASH (metabolic dysfunction-associated steatohepatitis). The purpose of this study is to find out how well a medicine called BI 770371 is tolerated.
- Trial name
- NCT06675929
- Testing
- BI 770371
- Where
- 13 sites in United States
- Volunteers
- 28 people
- Sponsor
- Boehringer Ingelheim
Morbid Obesity, Steatohepatitis
Identification of Protective and Worsening Steatohepatitis (NASH) Factors
The main aim of this work will be to identify a profile of gene expression by microarray in the liver which might allow to differentiate obese subjects having a normal liver from those with steatohepatitis or steatosis.
- Conditions
- Morbid Obesity, Steatohepatitis, Steatosis
- Trial name
- NCT00914446
- Testing
- hepatic biopsies
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Obesity, NAFLD
The Impact of Bariatric Surgery on Non-alcoholic Fatty Liver Disease
Up to 300 million people have a BMI over 30kg/m2. Obesity is the cause of many serious diseases, such as type 2 diabetes, hypertension and NAFLD.
- Trial name
- NCT02828579
- Testing
- Bariatric surgery
- Volunteers
- 20 people
- Sponsor
- Jagiellonian University
Hepatitis C, Chronic, Non-Alcoholic Fatty Liver Disease
Intra-Individual Reproducibility of the Non-Invasive Assessment of the Portal Circulation
HepQuant tests are new liver tests that are being developed to accurately measure liver function with sensitivity and specificity while being safe and non-invasive.
- Trial name
- Repro (NCT01579162)
- Testing
- Cholate-24-13C (IND 65121) & Cholate-2,2,4,4-d4 (IND 65123)
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- HepQuant, LLC
Nonalcoholic Steatohepatitis (NASH)
Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH)
The primary objective of this study is to evaluate the safety and tolerability of GS-9674 in participants with nonalcoholic steatohepatitis (NASH).
- Trial name
- NCT02854605
- Testing
- GS-9674
- Where
- 37 sites in United States, Canada and 4 more
- Volunteers
- 140 people
- Sponsor
- Gilead Sciences
Hepatic Steatosis
Quantitative US for Hepatic Steatosis
The purpose of this study is to investigate the diagnostic performance of quantitative ultrasound imaging parameter for the assessment of hepatic steatosis in patients with non-alcoholic fatty liver disease using magnetic…
- Trial name
- NCT04180631
- Testing
- Quantitative ultrasound imaging parameter (QUS)
- Where
- South Korea
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Steatohepatitis, Nonalcoholic
Formula Diet Treatment for NASH Patients.
Non-alcoholic steatohepatitis (NASH) - also called fatty liver - is medically a serious problem because the liver tissue becomes fatty and stiff, and inflammatory reactions occur.
- Trial name
- NASH (NCT04707651)
- Testing
- Formula diet
- Where
- 2 sites in Germany
- Volunteers
- 20 people
- Sponsor
- West German Center of Diabetes and Health
Metabolic-associated Fatty Liver Disease (MAFLD)
Evaluation of the Effectiveness of the Use of a Carnitine-Orotate Complex and Biphenyl Dimethyl Dicarboxylate in the Pathogenetic Therapy of Metabolic-associated Fatty Liver Disease: a Prospective Cohort Study
The goal of this observational study is to learn the effectiveness and safety of the use of Carnitine-Orotate Complex and Biphenyl Dimethyl Dicarboxylate in the pathogenetic therapy of metabolic-associated fatty liver disease…
- Trial name
- NCT06078722
- Where
- 7 sites in Kazakhstan
- Volunteers
- 264 people
- Sponsor
- Kazakh Association of Internal Medicine Specialists
Non-alcoholic Fatty Liver Disease
Effect of Empagliflozin on Liver Fat in Non-diabetic Patients
Non-alcoholic fatty liver disease (NAFLD) is a global epidemic with a prevalence of 25%. Currently therapies for NAFLD patients without diabetes mellitus (DM) are limited, and are associated with various adverse side effects.
- Trial name
- NCT04642261
- Testing
- Empagliflozin 10 MG
- Where
- Hong Kong
- Volunteers
- 98 people
- Sponsor
- The University of Hong Kong
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.